BR112023025242A2 - Vetor de liberação de sirna - Google Patents

Vetor de liberação de sirna

Info

Publication number
BR112023025242A2
BR112023025242A2 BR112023025242A BR112023025242A BR112023025242A2 BR 112023025242 A2 BR112023025242 A2 BR 112023025242A2 BR 112023025242 A BR112023025242 A BR 112023025242A BR 112023025242 A BR112023025242 A BR 112023025242A BR 112023025242 A2 BR112023025242 A2 BR 112023025242A2
Authority
BR
Brazil
Prior art keywords
agent
negatively charged
phosphonium
therapeutic
sirna
Prior art date
Application number
BR112023025242A
Other languages
English (en)
Inventor
Altab Shaikh
Panangipalli Sravya
Kumar Neeli Praveen
Rajamannar Thennati
Rajkumar Banerjee
Singuru Gajalakshmi
Srigiridhar Kotamraju
Reddy Bathula Surendar
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Publication of BR112023025242A2 publication Critical patent/BR112023025242A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Medicinal Preparation (AREA)

Abstract

vetor de liberação de sirna. .é fornecido um complexo de um anfifílico de fosfônio 6,7-di-hidroxicumarina juntamente com um agente carregado negativamente. o complexo se automonta em uma nanopartícula ou vetor não viral para facilitar a distribuição do agente carregado negativamente. o agente carregado negativamente pode ser um agente terapêutico ou um agente de diagnóstico. assim, a presente invenção fornece um método de entrega de tais agentes carregados negativamente a uma célula alvo e, em particular, facilita a entrega de um agente terapêutico ou de diagnóstico através da membrana plasmática, bem como um método de tratamento ou diagnóstico através da entrega do agente terapêutico. ou agente de diagnóstico. o anfifílico 6,7-di-hidroxi cumarina fosfônio pode ser mito-esc e o agente carregado negativamente pode ser um ácido nucleico, tal como sirna. além disso, acredita-se que o anfifílico 6,7-di-hidroxi cumarina fosfônio seja eficaz no tratamento do câncer
BR112023025242A 2021-06-04 2022-06-03 Vetor de liberação de sirna BR112023025242A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202111024926 2021-06-04
PCT/IB2022/055214 WO2022254405A1 (en) 2021-06-04 2022-06-03 siRNA DELIVERY VECTOR

Publications (1)

Publication Number Publication Date
BR112023025242A2 true BR112023025242A2 (pt) 2024-02-20

Family

ID=82558096

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025242A BR112023025242A2 (pt) 2021-06-04 2022-06-03 Vetor de liberação de sirna

Country Status (8)

Country Link
US (1) US20240277851A1 (pt)
EP (1) EP4346902A1 (pt)
JP (1) JP2024521209A (pt)
CN (1) CN117396227A (pt)
AU (1) AU2022287326A1 (pt)
BR (1) BR112023025242A2 (pt)
CA (1) CA3220535A1 (pt)
WO (1) WO2022254405A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116159145A (zh) * 2023-01-31 2023-05-26 四川大学 含七叶皂苷和/或其盐化合物的转染复合物在促转染的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2585171B (en) * 2015-02-19 2021-03-24 Council Scient Ind Res An antioxidant compound having anti atherosclerotic effect and preparation thereof
US11213960B2 (en) 2018-09-17 2022-01-04 John AMBIELLI Multi-tool and storage device
AR127082A1 (es) * 2019-11-22 2023-12-20 Council Scient Ind Res Compuestos antiinflamatorios para el tratamiento de trastornos cutáneos

Also Published As

Publication number Publication date
US20240277851A1 (en) 2024-08-22
CA3220535A1 (en) 2022-12-08
CN117396227A (zh) 2024-01-12
WO2022254405A1 (en) 2022-12-08
JP2024521209A (ja) 2024-05-28
EP4346902A1 (en) 2024-04-10
AU2022287326A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
Pu et al. Sono‐controllable and ROS‐sensitive CRISPR‐Cas9 genome editing for augmented/synergistic ultrasound tumor nanotherapy
BR112018073699A2 (pt) amino lipídios de sulfonamida catiônica e amino lipídios zwiteriônico anfifílicos
JOP20210207A1 (ar) مركبات ترابطية مستهدفة
BR112017013597A2 (pt) molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença.
NO20084199L (no) Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
BR112013027674A2 (pt) "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
BR112012015499A2 (pt) método de tratamento de fibrilação atrial
BR112013002655A2 (pt) novo tratamento de carcinoma de próstata
BR112014027942A2 (pt) dispersão de pó pró-lipossomal; composição farmacêutica; forma de dosagem oral; e método para tratar um indivíduo que necessite de terapia de testosterona
BR112023018944A2 (pt) Composição de terapia gênica e tratamento de cardiomiopatia arritmogênica ventricular direita
EP3818991A3 (en) Compositions and methods for treating diseases
BR112014032239A2 (pt) inibidores da família de mir-15 de micro-rnas
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
BR112015033053A2 (pt) método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit
BR112018008344A2 (pt) molécula de ácido nucleico, composição farmacêutica, vetor ou célula, método para prevenir, tratar ou melhorar uma doença, e, uso de uma composição
BR112023025242A2 (pt) Vetor de liberação de sirna
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
BR112023002453A2 (pt) Composições de agente de via de estresse de replicação e métodos para tratar câncer
BR112022013270A2 (pt) Sistemas e composições farmacêuticas para tratamento por injeção direta de uma população alvo de células
MX2020012652A (es) Oligonucleotido bicatenario especifico del gen de anfirregulina y composicion para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo.
BR112021024534A2 (pt) Métodos para o tratamento da deficiência de alfa-1 antitripsina (aatd)
ATE418965T1 (de) Medikamentöse gezielte lokale lipolyse
BR112013002945A2 (pt) composição farmacâutica formulada com agente de eco-contraste de microbolhas e um ácido nucleico terapêutico de interesse para uso em um método para tratamento de uma doença ocular em um sujeito